Use of Lipid Emulsion in the Resuscitation of a Patient With Prolonged Cardiovascular Collapse After Overdose of Bupropion and Lamotrigine
Animal studies show efficacy of intravenous lipid emulsion in the treatment of severe cardiotoxicity associated with local anesthetics, clomipramine, and verapamil, possibly by trapping such lipophilic drugs in an expanded plasma lipid compartment (“lipid sink”). Recent case reports describe lipid infusion for the successful treatment of refractory cardiac arrest caused by parenteral administration of local anesthetics, but clinical evidence has been lacking for lipid’s antidotal efficacy on toxicity caused by ingested medications. A 17-year-old girl developed seizure activity and cardiovascular collapse after intentional ingestion of up to 7.95 g of bupropion and 4 g of lamotrigine. Standard cardiopulmonary resuscitation for 70 minutes was unsuccessful in restoring sustained circulation. A 100-mL intravenous bolus of 20% lipid emulsion was then administered, and after 1 minute an effective sustained pulse was observed. The patient subsequently manifested significant acute lung injury but had rapid improvement in cardiovascular status and recovered, with near-normal neurologic function. Serum bupropion levels before and after lipid infusion paralleled triglyceride levels. This patient developed cardiovascular collapse because of intentional, oral overdose of bupropion and lamotrigine that was initially refractory to standard resuscitation measures. An infusion of lipid emulsion was followed rapidly by restoration of effective circulation. Toxicologic studies are consistent with the lipid sink theory of antidotal efficacy.
To access this article, please choose from the options below
Supervising editors: Lewis S. Nelson, MD; G. Randall Bond, MDFunding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. Since acceptance of the paper, GW was awarded US patent 7,261,903 B1, “Lipid emulsion in the treatment of systemic poisoning.” GW has no equity interest or financial agreements with any company or commercial entity related to this method and has never received salary or support from any company related to the method. GW does not intend to prohibit or restrict the practice of this method on any patient. GW and FH also co-authored a response to a letter to the editor, publishing in this issue.Publication dates: Available online September 4, 2007.Reprints not available from the authors.
PII: S0196-0644(07)00717-2
doi:10.1016/j.annemergmed.2007.06.004
© 2008 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.
